Acyclovir 400 mg Once Daily Is NOT the Standard Prophylactic Regimen for Cold Sores
The standard prophylactic dose for preventing recurrent oral herpes (cold sores) is acyclovir 400 mg twice daily, not once daily. 1
Standard Suppressive Therapy Dosing
The CDC guidelines consistently recommend for daily suppressive therapy:
- Primary regimen: Acyclovir 400 mg orally twice daily 1
- Alternative regimen: Acyclovir 200 mg orally 3-5 times daily (to identify the lowest effective dose for each patient) 1
Clinical Efficacy Evidence
Daily suppressive therapy with acyclovir 400 mg twice daily reduces HSV recurrence frequency by at least 75% in patients with frequent recurrences (≥6 episodes per year). 1
A high-quality RCT demonstrated that acyclovir 400 mg twice daily significantly extended the median time to first recurrence (118 days vs 46 days with placebo, P=0.05) and reduced clinical recurrences by 53% (0.85 vs 1.80 episodes per 4-month period, P=0.009). 2 Virologically confirmed recurrences decreased by 71% (0.40 vs 1.40 episodes, P=0.003). 2
Important Clinical Considerations
Who Should Receive Prophylaxis
- Prophylaxis is indicated for immunocompetent patients with frequent recurrences (≥6 episodes per year). 1
- Safety and efficacy have been documented for continuous daily therapy for up to 5-6 years. 1, 3
Duration and Reassessment
- After 1 year of continuous suppressive therapy, acyclovir should be discontinued to reassess the patient's recurrence rate, as recurrence frequency naturally decreases over time in many patients. 1
Limitations of Suppressive Therapy
- Suppressive treatment does not eliminate asymptomatic viral shedding or completely prevent transmission. 1
- Acyclovir neither eradicates latent virus nor affects subsequent risk, frequency, or severity of recurrences after discontinuation. 1
Resistance Concerns
- Acyclovir-resistant HSV strains have been isolated from some patients receiving suppressive therapy, but these have not been associated with treatment failure in immunocompetent patients. 1
Alternative Prophylactic Options
For patients seeking alternatives to twice-daily dosing:
- Valacyclovir 500 mg once daily is an FDA-approved option with improved bioavailability and simpler dosing, though it may be less effective in patients with very frequent recurrences (≥10 episodes per year). 4
- Sunscreen alone (SPF ≥15) can effectively prevent ultraviolet light-induced recurrences. 5, 6
Common Pitfall
Do not prescribe acyclovir 400 mg once daily for cold sore prophylaxis—this is an underdosing error. The evidence base and guideline recommendations uniformly support twice-daily dosing at this strength. 1, 2